In the last trading session, the stock price of Akers Biosciences Inc (NASDAQ:AKER) declined more than 5% to close the day at $0.230. The decline came at a share volume of 10.35 million compared to average share volume of 3.32 million. Post the recent decline, the market cap of firm was noted at $7.2 million.
Last month Akers Biosciences reported that its Health & Wellness product line is protected by 10 patents in the U.S., the EU, China, Hong Kong and Japan, with additional patents seeking in the EU and India; and 6 trademark registrations in the United States. The patents target three novel aspects of technology advanced by Akers Biosciences for the firm’s Akers Wellness™ line.
The preliminary group of three patents increase the U.S. protection already given to further nations and cover the innovative structure of the disposable cartridge which comprises the reagent for the finding of wellness markers in area of exhaled breath. The reagent limited within is analyzed utilizing optical scanning knowhow after contact with the subject’s breath sample and results in a quantitative outcome via the Akers Wellness™ application on the user’s tablet or smartphone. Comprised in the patent group are the innovative form factor, read elements and optical lens and the distinct ‘U’ shaped airflow pathway.
Another group of three patents comprise Akers’ BreathScan Lync™ technology. It is the new Bluetooth-supported reading device from company which allows users to track the outcome of Akers Wellness™ breath-based assessments through their mobile device. There is a third group which contains four patents focusing on the apparatus and device used to know ketone levels in exhaled breath suggestive of ketosis.
Akers Wellness™ breath tests are intended to help promote, encourage and/or track choices linked to general health and wellbeing. It intends to record an optimal metabolic state for endurance or fitness events.